Companies: 10,795·Total market cap: $144.5T
Immatics N.V.

Immatics N.V.

IMTXNASDAQHealthcare● Active
$9.22
$-0.57(-5.82%)
Market Cap$1.2B
P/E Ratio
52W High$12.41
52W Low$5.05
Overview

Immatics N.V. (IMTX) PE Ratio — Current & Historical Data

Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.

imtx · pe ratio · data through Dec 31, 2025

Core PE Ratio Metrics

Trailing 12 months · TTM

The price-to-earnings (P/E) ratio for Immatics N.V. (IMTX) measures how much investors pay for each dollar of the company's trailing earnings. IMTX's current PE ratio of N/A is calculated by dividing its stock price of $9.22 by its TTM earnings per share of -$1.59.

N/A
P/E Ratio (TTM)N/A — Company is not profitable (TTM)

Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31

Forward P/E
N/A
FY2027 est. EPS $-1.69
Based on 6 analysts
EPS (TTM)
-$1.59
TTM · diluted EPS
PEG Ratio
0.04
Below 1.0 · Growth adjusted
Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Immatics N.V. SEC 10-K & 10-Q filings · US GAAPUpdated: 2026-06-08

PE Ratio History

2018 – 2025 · Annual
PE Ratio (TTM)
5Y Avg 31.8x
EPS (Annual)

▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)

PE Ratio vs Peers

Biotechnology · 6 peers · Annual PE
CompanyMarket CapPE (Annual)vs AvgEPS (TTM)
Immatics N.V.
Immatics N.V.You
IMTX
$1.2BN/A-$1.59
Atai Beckley Inc.
Atai Beckley Inc.
ATAI
$1.4BN/A-$2.91
CureVac N.V.
CureVac N.V.
CVAC
$1.0B4.56x$0.72
Enliven Therapeutics, Inc.
Enliven Therapeutics, Inc.
ELVN
$2.0BN/A-$1.83
Inhibrx Biosciences, Inc.
Inhibrx Biosciences, Inc.
INBX
$1.3BN/A-$9.04
Nektar Therapeutics
Nektar Therapeutics
NKTR
$1.1BN/A-$9.73
Precigen, Inc.
Precigen, Inc.
PGEN
$1.1BN/A-$0.82

* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio

Annual PE Ratio History

Showing 8 of 8 years
Fiscal Year EndPE RatioEPS (TTM)YoY ChangePE vs Max
2025-12-31Latest
FY2025
$-1.61
2024-12-31
FY2024
49.04x$0.14
2023-12-31
FY2023
$-1.20
2022-12-31
FY2022
14.58x$0.56
2021-12-31
FY2021
$-1.51
2020-12-31
FY2020
$-4.78
2019-12-31
FY2019
$-0.50
2018-12-31
FY2018
$-0.50

▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API

About PE Ratio & Methodology

The price-to-earnings (P/E) ratio for Immatics N.V. (IMTX) measures how much investors pay for each dollar of the company's trailing earnings. IMTX's current PE ratio of N/A is calculated by dividing its stock price of $9.22 by its TTM earnings per share of -$1.59.

PE Ratio = Stock Price ÷ EPS (TTM)
= $9.22 ÷ -$1.59 = N/A
TTMTrailing Twelve Months — sum of the most recent 4 quarterly EPS figures
Forward PEStock price ÷ analyst consensus EPS estimate for the next fiscal year
PEGPE ÷ earnings growth rate — values below 1.0 suggest growth may justify the premium
Figures tie to SEC 10-K/10-Q and FMP ratio endpoints where noted.

Frequently asked questions

IMTX pe ratio · 6 questions

IMTX's current PE ratio is N/A as of 2026-06-08, based on a stock price of $9.22 and TTM EPS of -$1.59. Data sourced from Financial Modeling Prep via IMTX's SEC 10-K and 10-Q filings.

IMTX PE ratioWhat is IMTX PE ratioCurrent PE ratio of IMTXIMTX PE ratio today

Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Immatics N.V. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08